Yeo lab:Projects: Difference between revisions
mNo edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | ||
'''Dr. Yeo’s lab''' will focus on developing drug/gene delivery systems which can address these challenges in | '''Dr. Yeo’s lab''' will focus on developing drug/gene delivery systems which can address these challenges in '''delivery'''. Specific research projects include: | ||
*Developing | *Developing nanoparticles for tumor targeting. | ||
*Pulmonary drug delivery for | *Pulmonary drug delivery for local therapy. | ||
*Developing sustained protein delivery systems based on hydrogels and novel microencapsulation techniques for tissue engineering applications. | *Developing sustained protein delivery systems based on hydrogels and novel microencapsulation techniques for tissue engineering applications. | ||
|}<br style="clear:both" /> | |}<br style="clear:both" /> | ||
Revision as of 14:58, 29 January 2007
|
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Dr. Yeo’s lab will focus on developing drug/gene delivery systems which can address these challenges in delivery. Specific research projects include:
|
